{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:18:21Z","timestamp":1783423101489,"version":"3.54.6"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014487","name":"Clovis Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014487","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011772","name":"Novartis Farmac\u00e9utica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011772","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006546","name":"Angelini Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006546","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015756","name":"Cilag","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.esmoop.2022.100463","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T23:03:38Z","timestamp":1649372618000},"page":"100463","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy"],"prefix":"10.1016","volume":"7","author":[{"given":"E.","family":"Grande","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Alonso-Gordoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Reig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Garcia-del-Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Mendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Garc\u00eda-Donas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gonz\u00e1lez Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Arranz-Arija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Lopez-Criado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Molina-Cerrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Mellado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Alvarez-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"De Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Cu\u00e9llar-Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.M.","family":"Rodr\u00edguez-Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.F.","family":"Rodr\u00edguez-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Suarez-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2022.100463_bib1","series-title":"NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer-Version 4.2021","year":"2021"},{"key":"10.1016\/j.esmoop.2022.100463_bib2","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdz056","article-title":"Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Escudier","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100463_bib3","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.annonc.2020.11.016","article-title":"Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Powles","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100463_bib4","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100463_bib5","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100463_bib6","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100463_bib7","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100463_bib8","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100463_bib9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2018.11.031","article-title":"Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma","volume":"108","author":"Auvray","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2022.100463_bib10","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41416-018-0164-0","article-title":"Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma","volume":"119","author":"Powles","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2022.100463_bib11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ejca.2019.04.003","article-title":"Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors","volume":"114","author":"Shah","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2022.100463_bib12","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(19)30513-3","article-title":"Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study","volume":"20","author":"Ornstein","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100463_bib13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1470-2045(19)30735-1","article-title":"Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study","volume":"21","author":"Rini","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100463_bib14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejca.2020.05.009","article-title":"Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma","volume":"135","author":"McGregor","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2022.100463_bib15","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.clgc.2019.10.010","article-title":"Real-world clinical outcomes of pazopanib immediately after discontinuation of immunotherapy for advanced renal cell carcinoma","volume":"18","author":"Cao","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.esmoop.2022.100463_bib16","article-title":"Phase 2 trial of lenvatinib at 2 starting doses\u00a0+ everolimus in renal cell carcinoma (RCC). 19th Annual meeting of the international kidney cancer symposium (IKCS 2020)","volume":"18","author":"Pal","year":"2020","journal-title":"Kidney Cancer J"},{"key":"10.1016\/j.esmoop.2022.100463_bib17","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.clgc.2021.03.006","article-title":"Clinical effectiveness of second-line sunitinib following immuno-oncology therapy in patients with metastatic renal cell carcinoma: a real-world study","volume":"19","author":"Wells","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.esmoop.2022.100463_bib18","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.eururo.2019.07.048","article-title":"First-line immuno-oncology combination therapies in metastatic renal-cell carcinoma: results from the international metastatic renal-cell carcinoma database consortium","volume":"76","author":"Dudani","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.esmoop.2022.100463_bib19","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.euo.2019.11.001","article-title":"Outcomes of patients with metastatic renal cell carcinoma treated with targeted therapy after immuno-oncology checkpoint inhibitors","volume":"4","author":"Graham","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.esmoop.2022.100463_bib20","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41416-018-0104-z","article-title":"The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma","volume":"119","author":"Barata","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2022.100463_bib21","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/annonc\/mdw160","article-title":"Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma","volume":"27","author":"Nadal","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100463_bib22","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.eururo.2019.07.048","article-title":"First-line immuno-oncology combination therapies in metastatic renal-cell carcinoma: results from the International Metastatic Renal-cell Carcinoma Database Consortium","volume":"76","author":"Dudani","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.esmoop.2022.100463_bib23","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/annonc\/mdw160","article-title":"Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma","volume":"27","author":"Nadal","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100463_bib24","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s11523-020-00732-y","article-title":"Cabozantinib after a previous immune checkpoint inhibitor in metastatic renal cell carcinoma: a retrospective multi-institutional analysis","volume":"15","author":"Iacovelli","year":"2020","journal-title":"Target Oncol"},{"key":"10.1016\/j.esmoop.2022.100463_bib25","doi-asserted-by":"crossref","first-page":"S564","DOI":"10.1016\/j.annonc.2020.08.790","article-title":"718P A phase II study of patients with advanced or metastatic renal cell carcinoma (mRCC) receiving pazopanib after previous checkpoint inhibitor treatment","volume":"31","author":"Powles","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100463_bib26","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.4569","article-title":"A\u00a0phase 2 single-arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune checkpoint inhibitor: the BREAKPOINT trial (MeetUro trial 03-NCT03463681)","volume":"39","author":"Procopio","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100463_bib27","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1470-2045(14)71222-7","article-title":"The international metastatic renal cell carcinoma database consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study","volume":"16","author":"Ko","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100463_bib28","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100463_bib29","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ctrv.2011.12.009","article-title":"Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit","volume":"38","author":"Oudard","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2022.100463_bib30","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.eururo.2015.04.017","article-title":"SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer","volume":"68","author":"Eichelberg","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.esmoop.2022.100463_bib31","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/annonc\/mdx075","article-title":"Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC","volume":"28","author":"Knox","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100463_bib32","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.clgc.2019.06.002","article-title":"Clinical efficacy and complication rate of sunitinib 2\/1 versus 4\/2 schedule for the treatment of metastatic renal cell cancer: a systematic review and meta-analysis","volume":"17","author":"Chen","year":"2019","journal-title":"Clin Genitourin Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922000813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922000813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:26:17Z","timestamp":1761855977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922000813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S2059702922000813"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100463","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100463","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100463"}}